Base de dados : MEDLINE
Pesquisa : D02.886.489.534 [Categoria DeCS]
Referências encontradas : 5172 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 518 ir para página                         

  1 / 5172 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29309107
[Au] Autor:Tarabar D; Kandolf-Sekulovic L; Tatomirovic Z; Mijuskovic Z; Milenkovic Z; Tarabar O; Pecelj-Brocic T
[Ti] Título:Cutaneous side effects caused by treatment for inflammatory bowel disease.
[So] Source:Vojnosanit Pregl;73(4):382-9, 2016 Apr.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Mh] Termos MeSH primário: Erupção por Droga/etiologia
Doenças Inflamatórias Intestinais/tratamento farmacológico
[Mh] Termos MeSH secundário: Corticosteroides/efeitos adversos
Anti-Inflamatórios não Esteroides/efeitos adversos
Azatioprina/efeitos adversos
Ciclosporina/efeitos adversos
Erupção por Droga/terapia
Seres Humanos
Imunossupressores/efeitos adversos
Mercaptopurina/efeitos adversos
Mesalamina/efeitos adversos
Metotrexato/efeitos adversos
Fator de Necrose Tumoral alfa/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Immunosuppressive Agents); 0 (Tumor Necrosis Factor-alpha); 4Q81I59GXC (Mesalamine); 83HN0GTJ6D (Cyclosporine); E7WED276I5 (Mercaptopurine); MRK240IY2L (Azathioprine); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE
[do] DOI:10.2298/VSP151123023D


  2 / 5172 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29200162
[Au] Autor:Valliyammai N; Nancy NK; Sagar TG; Rajkumar T
[Ad] Endereço:Departments of Molecular Oncology.
[Ti] Título:Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia.
[So] Source:J Pediatr Hematol Oncol;40(1):e1-e8, 2018 Jan.
[Is] ISSN:1536-3678
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:NOTCH1/FBXW7 mutations trigger oncogenic NOTCH1 signaling and its downstream target genes play crucial roles in the molecular pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL). In the present study, NOTCH1 and FBXW7 mutations were studied in 25 primary T-ALL samples. All 34 exons of NOTCH1 and hotspot exons (exon 9 and exon 10) of FBXW7 were polymerase chain reaction amplified and sequenced for mutations. Our results showed that 13/25 (52%) were NOTCH1-mutated, of which 11 patients (44%) showed mutation in the hotspot exons. Four patients (16%) had mutations in non-hotspot exons of NOTCH1. Notably, 2 T-ALL patients (8%) harbored mutations in both hotspot and non-hotspot exons of NOTCH1, whereas 2 patients (8%) had mutations in the hotspot exons of FBXW7. In all, 7 mutations were identified which were not previously reported. The real-time polymerase chain reaction study in 15 patients revealed that increased expression of activated NOTCH1 was found in NOTCH1/FBXW7 hotspot exon-mutated cases. In addition, NOTCH1/FBXW7-mutated patients had showed upregulated HES1, c-MYC, NOTCH3 gene expression. When survival analysis was performed including samples (n=50) from our previous study, an early treatment response and better survival was observed in NOTCH1/FBXW7 hotspot-mutated patients. Our study suggests that NOTCH1/FBXW7 hotspot-mutated T-ALL cases had better response to ALL BFM-95 protocol.
[Mh] Termos MeSH primário: Proteína 7 com Repetições F-Box-WD/genética
Mutação
Leucemia-Linfoma Linfoblástico de Células T Precursoras/genética
Prognóstico
Receptor Notch1/genética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Protocolos de Quimioterapia Combinada Antineoplásica
Asparaginase
Criança
Pré-Escolar
Ciclofosfamida
Citarabina
Análise Mutacional de DNA
Feminino
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Índia/epidemiologia
Lactente
Recém-Nascido
Masculino
Mercaptopurina
Metotrexato
Leucemia-Linfoma Linfoblástico de Células T Precursoras/diagnóstico
Leucemia-Linfoma Linfoblástico de Células T Precursoras/epidemiologia
Leucemia-Linfoma Linfoblástico de Células T Precursoras/mortalidade
Prednisona
Análise de Sobrevida
Vincristina
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (F-Box-WD Repeat-Containing Protein 7); 0 (FBXW7 protein, human); 0 (NOTCH1 protein, human); 0 (Receptor, Notch1); 04079A1RDZ (Cytarabine); 5J49Q6B70F (Vincristine); 8N3DW7272P (Cyclophosphamide); E7WED276I5 (Mercaptopurine); EC 3.5.1.1 (Asparaginase); VB0R961HZT (Prednisone); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.1097/MPH.0000000000001006


  3 / 5172 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29226420
[Au] Autor:Broekman MMTJ; Wanten GJ; de Jong DJ
[Ad] Endereço:Department of Gastroenterology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
[Ti] Título:Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors' reply.
[So] Source:Aliment Pharmacol Ther;47(1):130-131, 2018 01.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Envelhecimento
Doenças Inflamatórias Intestinais
[Mh] Termos MeSH secundário: Azatioprina
Genótipo
Seres Humanos
Imunossupressores
Mercaptopurina
Metiltransferases/genética
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Immunosuppressive Agents); E7WED276I5 (Mercaptopurine); EC 2.1.1.- (Methyltransferases); MRK240IY2L (Azathioprine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1111/apt.14395


  4 / 5172 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29226409
[Au] Autor:Willington AJ; Gearry RB
[Ad] Endereço:Department of Gastroenterology, Christchurch Hospital, Canterbury District Health Board, Christchurch, New Zealand.
[Ti] Título:Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing.
[So] Source:Aliment Pharmacol Ther;47(1):129-130, 2018 01.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Envelhecimento
Doenças Inflamatórias Intestinais
[Mh] Termos MeSH secundário: Azatioprina
Genótipo
Seres Humanos
Imunossupressores
Mercaptopurina
Metiltransferases/genética
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Immunosuppressive Agents); E7WED276I5 (Mercaptopurine); EC 2.1.1.- (Methyltransferases); MRK240IY2L (Azathioprine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1111/apt.14370


  5 / 5172 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29226406
[Au] Autor:Meijer B; de Boer NKH
[Ad] Endereço:Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands.
[Ti] Título:Letter: thiopurines - is less really more?
[So] Source:Aliment Pharmacol Ther;47(1):149, 2018 01.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Azatioprina
Mercaptopurina
[Mh] Termos MeSH secundário: Seres Humanos
Imunossupressores
Doenças Inflamatórias Intestinais
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Immunosuppressive Agents); E7WED276I5 (Mercaptopurine); MRK240IY2L (Azathioprine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1111/apt.14375


  6 / 5172 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28877179
[Au] Autor:Alsous M; Abu Farha R; Alefishat E; Al Omar S; Momani D; Gharabli A; McElnay J; Horne R; Rihani R
[Ad] Endereço:Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.
[Ti] Título:Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia.
[So] Source:PLoS One;12(9):e0183119, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Studies on children with Acute Lymphoblastic Leukemia (ALL) reported non-adherence in 2-54% of cases. The primary objective of this study was to assess rates of adherence to 6-MP using two different methods in children and adolescents with ALL. Secondary aim was to identify factors that influence adherence to 6-MP in children with ALL. METHODS: All eligible children with ALL who are (≤ 19) years old and receive 6-MP therapy for at least 1 month were approached to participate in the study. A total of 52 children with ALL and their primary caregivers were recruited. Adherence measures included an objective method (measuring 6-MP metabolites in packed Red Blood Cells (RBCs)) and a subjective method (using parent and child self-report via the Medication Adherence Report Scale; MARS; Adherence was defined as 90% or greater). RESULTS: Rates of adherence varied across the measurement methods. Packed RBCs sample analysis indicated forty-four patients (84.6%) to be adherent. Using the MARS questionnaires, a total of 49 children (94.2%) were classified as being adherent according to the parental MARS questionnaire scores, while all the 15 children (100%) who answered the MARS (child) questionnaire were classified as adherent. Overall adherence rate was 80.8% within the studied population. CONCLUSION: MARS scale was shown to overestimate adherence compared to measurement of 6-MP metabolites in the blood. A combination of both methods led to increased detection of non-adherence to thiopurine in children with ALL.
[Mh] Termos MeSH primário: Adesão à Medicação
Mercaptopurina/uso terapêutico
Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Criança
Análise por Conglomerados
Demografia
Feminino
Seres Humanos
Masculino
Pais
Fatores de Risco
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
E7WED276I5 (Mercaptopurine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170907
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183119


  7 / 5172 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28811125
[Au] Autor:Pelin M; Genova E; Fusco L; Marisat M; Hofmann U; Favretto D; Lucafò M; Taddio A; Martelossi S; Ventura A; Stocco G; Schwab M; Decorti G
[Ad] Endereço:Department of Life Sciences, University of Trieste, I-34127 Trieste, Italy.
[Ti] Título:Pharmacokinetics and pharmacodynamics of thiopurines in an in vitro model of human hepatocytes: Insights from an innovative mass spectrometry assay.
[So] Source:Chem Biol Interact;275:189-195, 2017 Sep 25.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:AIM: To apply an innovative LC-MS/MS method to quantify thiopurine metabolites in human hepatocytes and to associate them to cytotoxicity. METHODS: Immortalized human hepatocytes (IHH cells) were treated for 48 and 96 h, with 1.4 × 10 M azathioprine and 1.1 × 10 M mercaptopurine, concentrations corresponding to the IC values calculated after 96 h exposure in previous cytotoxicity analysis. After treatments, cells were collected for LC-MS/MS analysis to quantify 11 thiopurine metabolites with different level of phosphorylation and viable cells were counted by trypan blue exclusion assay to determine thiopurines in vitro effect on cell growth and survival. Statistical significance was determined by analysis of variance (ANOVA). RESULTS: Azathioprine and mercaptopurine had a significant time-dependent cytotoxic effect (p-value ANOVA = 0.012), with a viable cell count compared to controls of 55.5% and 67.5% respectively after 48 h and 23.7% and 36.1% after 96 h; no significant difference could be observed between the two drugs. Quantification of thiopurine metabolites evidenced that the most abundant metabolite was TIMP, representing 57.1% and 40.3% of total metabolites after 48 and 96 h. Total thiopurine metabolites absolute concentrations decreased over time: total mean content decreased from 469.9 pmol/million cells to 83.6 pmol/million cells (p-value ANOVA = 0.0070). However, considering the relative amount of thiopurine metabolites, TGMP content significantly increased from 11.4% cells to 26.4% (p-value ANOVA = 0.017). A significant association between thiopurine effects and viable cell counts could be detected only for MeTIMP: lower MeTIMP concentrations were associated with lower cell survival (p-value ANOVA = 0.011). Moreover, the ratio between MeTIMP and TGMP metabolites directly correlated with cell survival (p-value ANOVA = 0.037). CONCLUSION: Detailed quantification of thiopurine metabolites in a human hepatocytes model provided useful insights on the association between thioguanine and methyl-thioinosine nucleotides with cell viability.
[Mh] Termos MeSH primário: Purinas/análise
Purinas/farmacocinética
Espectrometria de Massas em Tandem
[Mh] Termos MeSH secundário: Azatioprina/análise
Azatioprina/metabolismo
Azatioprina/farmacocinética
Azatioprina/farmacologia
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Cromatografia Líquida de Alta Pressão
Hepatócitos/citologia
Hepatócitos/efeitos dos fármacos
Hepatócitos/metabolismo
Seres Humanos
Mercaptopurina/análise
Mercaptopurina/metabolismo
Mercaptopurina/farmacocinética
Mercaptopurina/farmacologia
Purinas/metabolismo
Purinas/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Purines); E7WED276I5 (Mercaptopurine); MRK240IY2L (Azathioprine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170817
[St] Status:MEDLINE


  8 / 5172 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28767288
[Au] Autor:Kutny MA; Alonzo TA; Gerbing RB; Wang YC; Raimondi SC; Hirsch BA; Fu CH; Meshinchi S; Gamis AS; Feusner JH; Gregory JJ
[Ad] Endereço:Matthew A. Kutny, University of Alabama at Birmingham, Birmingham, AL; Todd A. Alonzo, University of Southern California; Cecilia H. Fu, Children's Hospital Los Angeles, Los Angeles; Robert B. Gerbing and Yi-Cheng Wang, Children's Oncology Group, Monrovia; James H. Feusner, Children's Hospital and R
[Ti] Título:Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
[So] Source:J Clin Oncol;35(26):3021-3029, 2017 Sep 10.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose The Children's Oncology Group AAML0631 trial for newly diagnosed pediatric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the survival of patients receiving arsenic trioxide (ATO) consolidation and reduced doses of anthracyclines. Patients and Methods Patients age 2 to 21 years with de novo APL confirmed by PML-RARα polymerase chain reaction were stratified as standard risk (SR) or high risk (HR) on the basis of diagnostic WBC count. All patients received all-trans retinoic acid (ATRA) during induction, each consolidation course, and maintenance. All patients received two cycles of ATO therapy during consolidation 1, an additional two (SR) or three (HR) consolidation courses that included high-dose cytarabine and anthracycline, and maintenance therapy comprising ATRA, oral methotrexate, and mercaptopurine. Results One hundred one patients (66 SR and 35 HR) were evaluable for outcome. The 3-year overall survival was 94%, and event-free survival (EFS) was 91%. For SR and HR patients with APL, the overall survival was 98% versus 86% ( P = .003), and EFS was 95% versus 83% ( P = .03), respectively. The EFS for SR patients in AAML0631 was noninferior to that of patients in the AIDA 0493 historical control, which used a significantly higher anthracycline dose and did not include ATO consolidation. Relapse risk for patients in AAML0631 from end consolidation 1 (after ATO treatment) was only 4% at 3 years and did not differ significantly between SR and HR patients. Conclusion ATO consolidation cycles were well tolerated in pediatric patients with APL and allowed significant reduction in cumulative anthracycline doses while maintaining excellent survival and a low relapse risk for both SR and HR patients with APL.
[Mh] Termos MeSH primário: Antraciclinas/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Arsenicais/administração & dosagem
Leucemia Promielocítica Aguda/tratamento farmacológico
Óxidos/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Pré-Escolar
Quimioterapia de Consolidação
Citarabina/administração & dosagem
Intervalo Livre de Doença
Feminino
Estudo Historicamente Controlado
Seres Humanos
Masculino
Mercaptopurina/administração & dosagem
Metotrexato/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Anthracyclines); 0 (Arsenicals); 0 (Oxides); 04079A1RDZ (Cytarabine); E7WED276I5 (Mercaptopurine); S7V92P67HO (arsenic trioxide); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2016.71.6183


  9 / 5172 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28710878
[Au] Autor:Pranzatelli MR; Tate ED; Allison TJ
[Ad] Endereço:National Pediatric Neuroinflammation Organization, Inc., the National Pediatric Myoclonus Center, Orlando, FL, USA.
[Ti] Título:6-Mercaptopurine modifies cerebrospinal fluid T cell abnormalities in paediatric opsoclonus-myoclonus as steroid sparer.
[So] Source:Clin Exp Immunol;190(2):217-225, 2017 Nov.
[Is] ISSN:1365-2249
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to evaluate the capacity of 6-mercaptopurine (6-MP), a known immunosuppressant, to normalize cerebrospinal fluid (CSF) lymphocyte frequencies in opsoclonus-myoclonus syndrome (OMS) and function as a steroid sparer. CSF and blood lymphocytes were immunophenotyped in 11 children with OMS (without CSF B cell expansion) using a comprehensive panel of cell surface adhesion, activation and maturation markers by flow cytometry, and referenced to 18 paediatric controls. Drug metabolites, lymphocyte counts and liver function tests were used clinically to monitoring therapeutic range and toxicity. In CSF, adjunctive oral 6-MP was associated with a 21% increase in the low percentage of CD4 T cells in OMS, restoring the CD4/CD8 ratio. The percentage of CD4 T cells that were interferon (IFN)-γ was reduced by 66%, shifting the cytokine balance away from T helper type 1 (Th1) (proinflammatory) predominance. The percentage of natural killer (NK) cells decreased significantly in CSF (-32%) and blood (-67 to -82%). Low blood absolute lymphocyte count was more predictive of improvement in CSF lymphocyte proportions (correlated with % CD4 T cells) than the 6-thioguanine level (no correlation). 6-MP was difficult to titrate: 50% achieved the target absolute lymphocyte count (< 1·5 K/mm); 20%, the 'therapeutic' 6-thioguanine level; and 40% the non-toxic 6-methylmercaptopurine level. Side effects and transaminase elevation were mild and reversible. Clinical steroid-sparing properties and lowered relapse frequency were demonstrated. 6-MP displayed unique pharmacodynamic properties that may be useful in OMS and other autoimmune disorders. Its steroid sparer capacity is limited to children in whom the therapeutic window can be reached without limiting pharmacokinetic factors or side effects.
[Mh] Termos MeSH primário: Linfócitos T CD4-Positivos/efeitos dos fármacos
Líquido Cefalorraquidiano/citologia
Mercaptopurina/farmacologia
Síndrome de Opsoclonia-Mioclonia/líquido cefalorraquidiano
[Mh] Termos MeSH secundário: Administração Oral
Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD4-Positivos/patologia
Linfócitos T CD8-Positivos/imunologia
Líquido Cefalorraquidiano/imunologia
Pré-Escolar
Feminino
Seres Humanos
Imunofenotipagem
Inflamação
Interferon gama/biossíntese
Interferon gama/imunologia
Células Matadoras Naturais/imunologia
Contagem de Linfócitos
Masculino
Mercaptopurina/administração & dosagem
Mercaptopurina/análogos & derivados
Mercaptopurina/sangue
Mercaptopurina/farmacocinética
Neuroblastoma/imunologia
Células Th1/imunologia
Tioguanina/sangue
Transaminases/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
6V404DV25O (6-methylthiopurine); 82115-62-6 (Interferon-gamma); E7WED276I5 (Mercaptopurine); EC 2.6.1.- (Transaminases); FTK8U1GZNX (Thioguanine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170716
[St] Status:MEDLINE
[do] DOI:10.1111/cei.13015


  10 / 5172 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28710036
[Au] Autor:Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
[Ad] Endereço:Department of Medical & Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain. Electronic address: ggervasi@unex.es.
[Ti] Título:Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
[So] Source:Gene;628:72-77, 2017 Sep 10.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of the present work was to assess whether polymorphisms in genes coding for drug transport proteins may influence dosing, efficacy and toxicity of maintenance therapy with methotrexate (MTX) and 6-mercaptopurine (6MP) in childhood acute lymphoblastic leukemia (ALL). A total of 41 children with ALL were screened for 10 SNPs in the SLC19A1, ABCB1, ABCC2, ABCC4 and ABCG2 transporter genes by means of direct sequencing. Carriers of the ABCC4 934CC and ABCB1 1236TT genotypes received a lower percentage of the protocol-recommended starting dose of MTX (62.1 vs. 81.3% for 934CA carriers, p=0.001) and 6MP (73.1 vs. 87.7% for 1236CC/CT carriers; p=0.026), respectively. The C1236T SNP also increased the efficiency of myelosuppression. Median (and interquartile) number of blood tests with leukocytes levels <310 /L for the CC; CT and TT genotypes were 22 (13), 30.5 (11.75) and 33 (17.25), respectively (p=0.001). In addition, this SNP also correlated with the number of hematological adverse events (p=0.004 for the difference between same genotypes). The event more profoundly affected was neutropenia (p=0.004). In the same manner, the ABCC4 934CC genotype was also associated to more frequent hematological toxicity (p=0.041 vs. CT carriers) and raised LDH levels (p=0.004 vs. CT carriers); although only the latter association remained significant after correction by multiple testing. Overall, our findings indicate that variability in the ABCB1 and ABCC4 genes may confer higher sensitivity to maintenance chemotherapy of ALL, and therefore its determination may be helpful in individualizing this treatment.
[Mh] Termos MeSH primário: Transportadores de Cassetes de Ligação de ATP/genética
Antimetabólitos Antineoplásicos/uso terapêutico
Mercaptopurina/uso terapêutico
Metotrexato/uso terapêutico
Polimorfismo de Nucleotídeo Único
Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico
Leucemia-Linfoma Linfoblástico de Células Precursoras/genética
Proteína Carregadora de Folato Reduzido/genética
[Mh] Termos MeSH secundário: Adolescente
Antimetabólitos Antineoplásicos/administração & dosagem
Antimetabólitos Antineoplásicos/efeitos adversos
Criança
Pré-Escolar
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Lactente
Masculino
Mercaptopurina/administração & dosagem
Mercaptopurina/efeitos adversos
Metotrexato/administração & dosagem
Metotrexato/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimetabolites, Antineoplastic); 0 (Reduced Folate Carrier Protein); 0 (SLC19A1 protein, human); E7WED276I5 (Mercaptopurine); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170716
[St] Status:MEDLINE



página 1 de 518 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde